1. Covens AL: A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78: 269-274, 2000.

2. Thigpen T:, The if and when of surgical debulking for ovarian carcinoma. N Engl J Med 351:2544-2546, 2004.

3. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101-104, 1975.

4. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259, 2002.

5. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991.

6. Chi DS, Franklin CC, Levine DA, et al: Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94:650-654, 2004.

7. Hoskins WJ, Bundy BN, Thigpen JT, et al: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159166, 1992.

8. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974-979, 1994; discussion 979-980.

9. Chi DS, Eisenhauer EL, Lang J, et al: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559-564, 2006.

10. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:3443, 2006.

11. Bookman MA: GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24:5002, 2006.

12. Farias-Eisner R, Teng F, Oliveira M, et al: The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 55:108-110, 1994.

13. Heintz A, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. Int J Gynaecol Obstet 95(Suppl 1):S161-S192, 2006.

14. Eisenkop SM, Spirtos NM: What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82:489-497, 2001.

15. Akahira JI, Yoshikawa H, Shimizu Y, et al: Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 81:398^03, 2001.

16. Alphs HH, Zahurak ML, Bristow RE, et al: Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 103:1048-1053, 2006.

17. Bristow RE, del Carmen MG, Kaufman HS, et al: Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 197:565-574, 2003.

18. Obermair A, Hagenauer S, Tamandl D, et al: Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83:115-120, 2001.

19. Tamussino KF, Lim PC, Webb MJ, et al: Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol 80:7984, 2001.

20. Aletti GD, Dowdy SC, Podratz KC, et al: Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100:283-287, 2006.

21. Levine DA, Barakat RR, Hoskins WJ, et al: Procedures in Gynecologic Oncology. Informa Healthcare: New York and London, 2007, pp. 45-80.

22. Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278-287, 1999.

23. Bojalian MO, Machado GR, Swensen R, et al: Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review. Gynecol Oncol 93:557-560, 2004.

24. Magtibay PM, Adams PB, Silverman MB, et al: Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 102:369-374, 2006.

25. Morris M, Gershenson DM, Burke TW, et al: Splenectomy in gynecologic oncology: indications, complications, and technique. Gynecol Oncol 43:118-122, 1991.

26. Aletti GD, Dowdy S, Podratz KC, et al: Role of lymphadenec-tomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 195:18621868, 2005.

27. Panici PB, Maggioni A, Hacker N, et al: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560-566, 2005.

28. Chi DS, Venkatraman ES, Masson V, et al: The ability of pre-operative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227-231, 2000.

29. Brockbank EC, Ind TE, Barton DP, et al: Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 14:42-50, 2004.

30. Bristow RE, Duska LR, Lambrou NC, et al: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532-1540, 2000.

31. Byrom J, Widjaja E, Redman CW, et al: Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 109:369-375, 2002.

32. Dowdy SC, Mullany SA, Brandt KR, et al: The utility of computed tomography scans in predicting suboptimal cytoreduc-tive surgery in women with advanced ovarian carcinoma. Cancer 101:346-352, 2004.

33. Axtell A, Cass I, Li A, et al: Computed tomography predictors of primary suboptimal cytoreduction in patients with advanced ovarian cancer: a multi-institutional reciprocal validation study. [Abstract 57]. Gynecol Oncol 101:26, 2006.

34. Angioli R, Palaia I, Zullo MA, et al: Diagnostic open laparos-copy in the management of advanced ovarian cancer. Gynecol Oncol 100:455-461, 2006.

35. van der Burg ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629634, 1995.

36. Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489-2497, 2004.

37. Monk BJ, Disaia PJ: What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate. Int J Gynecol Cancer 15(Suppl 3):199-205, 2005.

38. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070-1076, 2006.

39. Greer BE, Bundy BN, Ozols RF, et al: Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol 99:71-79, 2005.

40. Obermair A, Sevelda P: Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand 80:432436, 2001.

41. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144-153, 2000.

42. Gadducci A, Iacconi P, Cosio S, et al: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79:344-349, 2000.

43. Morris M, Gershenson DM, Wharton JT, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34:334-338, 1989.

44. Segna RA, Dottino PR, Mandeli JP, et al: Secondary cytoreduc-tion for ovarian cancer following cisplatin therapy. J Clin Oncol 11:434-439, 1993.

45. Zang RY, Li ZT, Tang J, et al: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152-1161, 2004.

46. Munkarah AR, Coleman RL: Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95:273-280, 2004.

47. Harter P, Bois A, Hahmann M, et al: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 13:1702-1710, 2006.

48. Salani R, Santillan A, Zahurak ML, et al: Secondary cytoreduc-tive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109:685-691, 2007.

49. Tangjitgamol S, Levenback CF, Beller U, et al: Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 14:399^22, 2004.

50. Pothuri B, Vaidya A, Aghajanian C, et al: Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 89:306-313, 2003.

51. Feuer DJ, Broadley KE, Shepherd JH, et al: Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000: CD002764.

52. Jong P, Sturgeon J, Jamieson CG: Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg 38:454-457, 1995.

53. Pothuri B, Montemarano M, Gerardi M, et al: Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 96:330-334, 2005.

54. Dembo AJ, Davy M, Stenwig AE, et al: Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol, 75:263-273, 1990.

55. Sevelda P, Vavra N, Schemper M, et al: Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 65:2349-2352, 1990.

56. Vergote I, De Brabanter J, Fyles A, et al: Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176-182, 2001.

57. McGowan L, Lesher LP, Norris HJ, et al: Misstaging of ovarian cancer. Obstet Gynecol 65:568-572, 1985.

58. Buchsbaum HJ, Brady MF, Delgado G, et al: Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 169:226232, 1989.

59. Helewa ME, Krepart GV, Lotocki R: Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 154:282-286, 1986.

60. Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 250:3072-3076, 1983.

61. Le T, Adolph A, Krepart GV, et al: The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 85:351-355, 2002.

62. Benedetti Panici P, et al: XVI FIGO World Congress of Gyne-cology and Obstetrics, Washington, September. Int J Gynecol Obstet 70(Suppl 1): A1-A147, 2000.

63. Cass I, Li AJ, Runowicz CD, et al: Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 80:56-61, 2001.

64. Schilder JM, Thompson AM, DePriest PD, et al: Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 87:1-7, 2002.

65. Zanetta G, Chiari S, Rota S, et al: Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 104:1030-1035, 1997.

66. Benjamin I, Morgan MA, Rubin SC: Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 72:288-291, 1999.

67. Ayhan A, Gultekin M, Taskiran C, et al: Routine appendectomy in epithelial ovarian carcinoma: is it necessary? Obstet Gynecol 105:719-724, 2005.

68. Childers JM, Lang J, Surwit EA, et al: Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol 59:25-33, 1995.

69. Leblanc E, Querleu D, Narducci F, et al: Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol 94:624-629, 2004.

70. Tozzi R, Kohler C, Ferrara A, et al: Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol 93:199-203, 2004.

71. Chi DS, Abu-Rustum NR, Sonoda Y, et al: The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 192:1614-1619, 2005.

72. Medeiros LR, Rosa DD, Edelweiss MI, et al: Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer 15:192202, 2005.

73. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:11171130, 2003.

74. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001.

75. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002.

76. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002.

77. Finch A, Beiner M, Lubinski J, et al: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185192, 2006.

78. Kauff ND, Barakat RR: Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Gynecol Oncol 93:277-279, 2004.

79. Harlow BL, Weiss NS, Lofton S: Epidemiology of borderline ovarian tumors. J Natl Cancer Inst 78:71-74, 1987.

80. Tinelli R, Tinelli A, Tinelli FG, et al: Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 100:185191, 2006.

81. Lin PS, Gershenson DM, Bevers MW, et al: The current status of surgical staging of ovarian serous borderline tumors. Cancer 85:905-911, 1999.

82. Morris RT, Gershenson DM, Silva EG, et al: Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 95:541-547, 2000.

83. Zanetta G, Rota S, Chiari S, et al: Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19:2658-2664, 2001.

84. Seidman JD, Kurman, R.J: Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539-557, 2000.

85. Geomini P, Bremer G, Kruitwagen R, et al: Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 96:1-9, 2005.

86. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al: Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 35:949-960, 2004.

87. Barakat RR, Benjamin I, Lewis JL Jr, et al: Platinum based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 59:390-393, 1995.

88. Kliman L, Rome RM, Fortune DW: Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol 68:338-344, 1986.

89. Nation JG, Krepart GV: Ovarian carcinoma of low malignant potential: staging and treatment. Am J Obstet Gynecol 154:290-293, 1986.

90. Chambers JT, Merino MJ, Kohorn El, et al: Borderline ovarian tumors. Am J Obstet Gynecol 159:1088-1094, 1988.

91. Hopkins MP, Morley GW: The second-look operation and tumors of the ovary: a study of 76 cases. Obstet Gynecol 74:375-378, 1989.

92. Gershenson DM, Silva EG: Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 65:578585, 1990.

93. Sutton GP, Bundy BN, Omura GA, et al: Stage lll ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study).

Gynecol Oncol 41:230-233, 1991.

94. Gershenson DM, Silva EG, Tortolero-Luna G, et al: Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 83:2157-2163, 1998.

95. Longacre TA, McKenney JK, Tazelaar HD, et al: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29:707-723, 2005.

96. Crispens MA, Bodurka D, Deavers M, et al: Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3-10, 2002.

97. Kurman RJ, Norris HJ: Malignant germ cell tumors of the ovary. Hum Pathol 8:551-564, 1977.

98. Peccatori F, Bonazzi C, Chiari S, et al: Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 86:367-372, 1995.

99. Zanetta G, Bonazzi C, Cantu M, et al: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 19:1015-1120, 2001.

100. Slayton RE, Park RC, Silverberg SG, et al: Vincristine, dacti-nomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 56:243-248, 1985.

101. Williams SD, Blessing JA, Moore DH, et al: Cisplatin, vinblas-tine, and bleomycin in advanced and recurrent ovarian germ-

cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 111:22-27, 1989.

102. Bafna UD, Umadevi K, Kumaran C, et al: Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 11:300-304, 2001.

103. Munkarah A, Gershenson DM, Levenback C, et al: Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 55:217-223, 1994.

104. Rezk Y, Sheinfeld J, Chi DS: Prolonged survival following salvage surgery for chemorefractory ovarian immature tera-toma: a case report and review of the literature. Gynecol Oncol 96:883-887, 2005.

105. Andre F, Fizazi K, Culine S, et al: The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 36:1389-1394, 2000.

106. Zagame L, Pautier P, Duvillard P, et al: Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol 108:509-514, 2006.

107. Comerci JT Jr, Licciardi F, Bergh PA, et al: Mature cystic tera-toma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol 84:22-28, 1994.

108. Chan JK, Zhang M, Kaleb V, et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—a multivariate analysis. Gynecol Oncol 96:204-209, 2005.

109. Evans AT III, Gaffey TA, Malkasian GD Jr, et al: Clinicopatho-logic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 55:231-238, 1980.

110. Sehouli J, Drescher FS, Mustea A, et al: Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 24:1223-1239, 2004.

111. Gershenson DM, Morris M, Burke TW, et al: Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 87:527-531, 1996.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment